These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

285 related articles for article (PubMed ID: 20964595)

  • 1. Safety and maximum tolerated dose of superselective intraarterial cerebral infusion of bevacizumab after osmotic blood-brain barrier disruption for recurrent malignant glioma. Clinical article.
    Boockvar JA; Tsiouris AJ; Hofstetter CP; Kovanlikaya I; Fralin S; Kesavabhotla K; Seedial SM; Pannullo SC; Schwartz TH; Stieg P; Zimmerman RD; Knopman J; Scheff RJ; Christos P; Vallabhajosula S; Riina HA
    J Neurosurg; 2011 Mar; 114(3):624-32. PubMed ID: 20964595
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Superselective intraarterial cerebral infusion of cetuximab after osmotic blood/brain barrier disruption for recurrent malignant glioma: phase I study.
    Chakraborty S; Filippi CG; Wong T; Ray A; Fralin S; Tsiouris AJ; Praminick B; Demopoulos A; McCrea HJ; Bodhinayake I; Ortiz R; Langer DJ; Boockvar JA
    J Neurooncol; 2016 Jul; 128(3):405-15. PubMed ID: 26945581
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Superselective intraarterial cerebral infusion of bevacizumab: a revival of interventional neuro-oncology for malignant glioma.
    Riina HA; Fraser JF; Fralin S; Knopman J; Scheff RJ; Boockvar JA
    J Exp Ther Oncol; 2009; 8(2):145-50. PubMed ID: 20192120
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Intraarterial delivery of bevacizumab and cetuximab utilizing blood-brain barrier disruption in children with high-grade glioma and diffuse intrinsic pontine glioma: results of a phase I trial.
    McCrea HJ; Ivanidze J; O'Connor A; Hersh EH; Boockvar JA; Gobin YP; Knopman J; Greenfield JP
    J Neurosurg Pediatr; 2021 Oct; 28(4):371-379. PubMed ID: 34359048
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Durability of single dose intra-arterial bevacizumab after blood/brain barrier disruption for recurrent glioblastoma.
    Chakraborty S; Filippi CG; Burkhardt JK; Fralin S; Ray A; Wong T; Ortiz R; Langer DJ; Boockvar JA
    J Exp Ther Oncol; 2016 Nov; 11(4):261-267. PubMed ID: 27849336
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Intra-arterial delivery of bevacizumab after blood-brain barrier disruption for the treatment of recurrent glioblastoma: progression-free survival and overall survival.
    Burkhardt JK; Riina H; Shin BJ; Christos P; Kesavabhotla K; Hofstetter CP; Tsiouris AJ; Boockvar JA
    World Neurosurg; 2012 Jan; 77(1):130-4. PubMed ID: 22405392
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Bevacizumab for recurrent malignant gliomas: efficacy, toxicity, and patterns of recurrence.
    Norden AD; Young GS; Setayesh K; Muzikansky A; Klufas R; Ross GL; Ciampa AS; Ebbeling LG; Levy B; Drappatz J; Kesari S; Wen PY
    Neurology; 2008 Mar; 70(10):779-87. PubMed ID: 18316689
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy, safety and patterns of response and recurrence in patients with recurrent high-grade gliomas treated with bevacizumab plus irinotecan.
    Zuniga RM; Torcuator R; Jain R; Anderson J; Doyle T; Ellika S; Schultz L; Mikkelsen T
    J Neurooncol; 2009 Feb; 91(3):329-36. PubMed ID: 18953493
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Bevacizumab and dose-intense temozolomide in recurrent high-grade glioma.
    Verhoeff JJC; Lavini C; van Linde ME; Stalpers LJA; Majoie CBLM; Reijneveld JC; van Furth WR; Richel DJ
    Ann Oncol; 2010 Aug; 21(8):1723-1727. PubMed ID: 20064829
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Metabolic response of glioblastoma to superselective intra-arterial cerebral infusion of bevacizumab: a proton MR spectroscopic imaging study.
    Jeon JY; Kovanlikaya I; Boockvar JA; Mao X; Shin B; K Burkhardt J; Kesavabhotla K; Christos P; Riina H; Shungu DC; Tsiouris AJ
    AJNR Am J Neuroradiol; 2012 Dec; 33(11):2095-102. PubMed ID: 22576886
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treatment with bevacizumab plus carboplatin for recurrent malignant glioma.
    Thompson EM; Dosa E; Kraemer DF; Neuwelt EA
    Neurosurgery; 2010 Jul; 67(1):87-93. PubMed ID: 20559095
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Bevacizumab for recurrent malignant gliomas: efficacy, toxicity, and patterns of recurrence.
    Mrugala MM
    Neurology; 2009 Feb; 72(8):773; author reply 773-4. PubMed ID: 19248218
    [No Abstract]   [Full Text] [Related]  

  • 13. Rechallenging Recurrent Glioblastoma with Intra-Arterial Bevacizumab with Blood Brain-Barrier Disruption Results in Radiographic Response.
    Faltings L; Kulason KO; Patel NV; Wong T; Fralin S; Li M; Schneider JR; Filippi CG; Langer DJ; Ortiz R; Boockvar JA
    World Neurosurg; 2019 Nov; 131():234-241. PubMed ID: 31351210
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antiangiogenic therapy using bevacizumab in recurrent high-grade glioma: impact on local control and patient survival.
    Narayana A; Kelly P; Golfinos J; Parker E; Johnson G; Knopp E; Zagzag D; Fischer I; Raza S; Medabalmi P; Eagan P; Gruber ML
    J Neurosurg; 2009 Jan; 110(1):173-80. PubMed ID: 18834263
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Apparent diffusion coefficient changes predict survival after intra-arterial bevacizumab treatment in recurrent glioblastoma.
    Galla N; Chiang G; Chakraborty S; Singh R; John Tsiouris A; Boockvar J; Kovanlikaya I
    Neuroradiology; 2017 May; 59(5):499-505. PubMed ID: 28343250
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Bevacizumab-induced diffusion-restricted lesions in malignant glioma patients.
    Rieger J; Bähr O; Müller K; Franz K; Steinbach J; Hattingen E
    J Neurooncol; 2010 Aug; 99(1):49-56. PubMed ID: 20035366
    [TBL] [Abstract][Full Text] [Related]  

  • 17. 10 Questions about the use of bevacizumab in the management of recurrent malignant gliomas.
    Chamberlain MC
    Neurologist; 2010 Jan; 16(1):56-60. PubMed ID: 20065801
    [No Abstract]   [Full Text] [Related]  

  • 18. Imaging response criteria for recurrent gliomas treated with bevacizumab: role of diffusion weighted imaging as an imaging biomarker.
    Jain R; Scarpace LM; Ellika S; Torcuator R; Schultz LR; Hearshen D; Mikkelsen T
    J Neurooncol; 2010 Feb; 96(3):423-31. PubMed ID: 19859666
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phase I study of panobinostat in combination with bevacizumab for recurrent high-grade glioma.
    Drappatz J; Lee EQ; Hammond S; Grimm SA; Norden AD; Beroukhim R; Gerard M; Schiff D; Chi AS; Batchelor TT; Doherty LM; Ciampa AS; Lafrankie DC; Ruland S; Snodgrass SM; Raizer JJ; Wen PY
    J Neurooncol; 2012 Mar; 107(1):133-8. PubMed ID: 21984064
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Advantages of high b-value diffusion-weighted imaging to diagnose pseudo-responses in patients with recurrent glioma after bevacizumab treatment.
    Yamasaki F; Kurisu K; Aoki T; Yamanaka M; Kajiwara Y; Watanabe Y; Takayasu T; Akiyama Y; Sugiyama K
    Eur J Radiol; 2012 Oct; 81(10):2805-10. PubMed ID: 22100373
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.